Navigation Links
Nuvo Research and Covidien sign U.S. license and development agreement for Pennsaid(R) and Pennsaid Plus(R)
Date:6/16/2009

MISSISSAUGA, ON, June 16 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI) a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies, today announced that it has entered into a license and development agreement with Mallinckrodt Inc., a subsidiary of Covidien (NYSE: COV), a leading global provider of healthcare products, granting it exclusive rights to market and sell Pennsaid(R), and its follow-on product, Pennsaid Plus(R), in the United States.

Pennsaid and Pennsaid Plus are Nuvo's topical non-steroidal anti-inflammatory drug ("NSAID") candidates. Nuvo has been advised by the U.S. Food and Drug Administration ("FDA") that it expects to respond to Nuvo's resubmitted new drug application for Pennsaid by August 5, 2009.

Under the terms of the license and development agreement, Nuvo will receive an up-front, non-refundable payment of US$10 million. In addition, Nuvo is eligible to receive a US$15 million milestone payment on Pennsaid's approval by the FDA, which will increase to US$20 million if certain labeling criteria are agreed to by the FDA. Nuvo will receive royalties on net U.S. sales of Pennsaid and Pennsaid Plus at rates that are consistent with industry standards for products at similar stages of development. Nuvo will be eligible to receive additional escalating sales milestone payments for the products totaling up to US$100 million.

Covidien will assume responsibility for all future development activities and expenses for Pennsaid Plus, including two Phase 3 clinical trials that Covidien expects to commence in 2010. Covidien has a right to negotiate with Nuvo on an exclusive basis for a period of 90 days to expand the licensed territory to include additional unlicensed countries worldwide. Nuvo will manufacture and supply Pennsaid and Pennsaid Plus to Covidien from its existing manufacturing facility in Varennes, Quebec.

Covidien is a leading global healthcare products company with revenues of nearly US$10 billion in 2008, and more than 41,000 employees in 59 countries worldwide. Its products are sold in more than 140 countries. A market study commissioned by Nuvo estimates that the market for topical NSAIDs will grow to US$2 billion annually within five years.

"Covidien is an ideal partner with the infrastructure, market reach, resources and commitment to maximize the commercial potential of Pennsaid and Pennsaid Plus," said Dan Chicoine, Chairman of Nuvo. "It is aggressively adding resources to maximize the value of the Pennsaid/Pennsaid Plus franchise and pursue its strategy of becoming a global presence in the treatment of pain."

About Pennsaid and Pennsaid Plus

Pennsaid, Nuvo's lead product, combines a transdermal carrier (containing dimethyl sulfoxide, popularly known as "DMSO") with diclofenac sodium, a leading non-steroidal anti-inflammatory drug ("NSAID"), and delivers the active drug through the skin directly to the site of pain. Pennsaid Plus is the follow-on product candidate to Pennsaid. Pennsaid Plus will feature a twice-daily dosing regime as a gel formulation.

About Nuvo Research Inc.

Nuvo is focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies. Nuvo's lead product is Pennsaid, a topical non-steroidal anti-inflammatory drug (NSAID). Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of topical and transdermal products targeting a variety of indications.

Nuvo is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany and a research and development Center in San Diego, California. For more information, please visit www.nuvoresearch.com

This document contains forward-looking statements. Some forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "indicates" or similar expressions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Nuvo considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but caution that these assumptions regarding future events, many of which are beyond the control of the Company, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report, as well as in Nuvo's Annual Information Form for the year ended December 31, 2008. Nuvo disclaims any intention or obligation to update or revise any forward-looking statements whether a result of new information or future events, except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company's ongoing quarterly filings, annual report and Annual Information Form and other filings found on SEDAR at www.sedar.com


'/>"/>
SOURCE Nuvo Research Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thomson Reuters Partners with Research4Life to Bring Scientific Research Information Resources to Developing Countries Around the World
2. Vanderbilt researchers pioneer an advanced sepsis detection and management system
3. MUHC researcher awarded $500,000 to study pathogenesis of infectious disease
4. Health research agencies form global alliance to curb humanitys most fatal diseases
5. Hebrew University research leads to advanced trials of new cancer treatment
6. Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference
7. HITSP Begins Harmonization Process for Use of Electronic Health Records in Clinical Research
8. High Activity, Plant Based Diamine Oxidase Enzyme Introduced by Bio-Research Products
9. New Research Suggests Strong Link Between Sweetened Caloric Beverages and Metabolic Syndrome
10. National Hispanic Medical Association to Focus Health Reform on Health Disparities and Comparative Effectiveness Research
11. USC researchers identify DNA mutation that occurs at beginning point of T-cell lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Tel Aviv (PRWEB) , ... May 31, 2016 ... ... in the May 4, 2016 Cool Vendors in Security Infrastructure Protection report by ... areas and publishes a series of research reports evaluating these innovative vendors and ...
(Date:5/31/2016)... PLAINSBORO, N.J. (PRWEB) , ... May 31, 2016 ... ... digital and print media enterprise focused on patients with cancer, has added ... provide readers and website visitors with more timely content on continuing successful careers ...
(Date:5/30/2016)... ... May 30, 2016 , ... Zane Benefits, the leader in ... original infographic, " Health Benefits Reimbursement Compliance Timeline ." , The new ... with various federal regulations and reforms. , Navigating the new health reforms can ...
(Date:5/29/2016)... ... 29, 2016 , ... Whole Health Supply is happy to announce a new ... available to the public. This is an unusual clipper because it opens to a ... , Everything about this product is concentrated on ease of use, functionality and durability. ...
(Date:5/28/2016)... ... ... May 26, 2016- In search of the K. Warriors, Shaolin Institute is ... Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 West Interstate 65 ... by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This is the 28th ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 31, 2016 RnRMarketResearch.com adds "Asthma ... comparative analysis of Asthma therapy at various stages, therapeutics ... of administration (RoA) and molecule type, along with latest ... reviews key players involved in the therapeutic development for ... Complete report on H1 2016 pipeline review ...
(Date:5/30/2016)... 30, 2016 On 28 May, 194 ... by 2030. At the 69 th World Health Assembly, ... Hepatitis Strategy, signalling the greatest global commitment in viral hepatitis ... eliminating hepatitis B and C by 2030 and includes a ... reduce annual deaths by 65% and increase treatment to 80%, ...
(Date:5/27/2016)... LabStyle Innovations Corp . ( NASDAQ: DRIO ... that the Company,s Chief Financial Officer, Zvi Ben-David ... 1-2 in New York, NY and ... Los Angeles, CA. During his ... including the U.S. FDA Clearance and commercial launch of the ...
Breaking Medicine Technology: